NCT04107727 2026-03-24
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
PETHEMA Foundation
Phase 2 Completed
Clinical Trials
9 trialsNCT03226418 2026-03-10
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
Phase 2 Completed
NCT02881086 2025-12-16
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University
Phase 3 Completed
NCT02421939 2025-12-04
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Completed
NCT00534469 2025-12-02
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
City of Hope Medical Center
Phase 2 Completed
NCT02310321 2025-09-02
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
Astellas Pharma Inc
Phase 1/2 Completed
NCT02185768 2025-07-04
IDASPHERE II
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT02937662 2025-05-30
Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
NCT01822015 2025-04-29
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Thomas Jefferson University
Phase EARLY_PHASE1 Completed